Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report on a case of alopecia areata in a mother and daughter with a 16-year gap suggests genetic predisposition and environmental triggers rather than direct transmission.

This study found that trichoscopic parameters in male androgenetic alopecia deteriorated progressively with increasing disease severity and were significantly linked to genetic, metabolic, and psychosocial factors.

This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.

This case report describes a 23-year-old woman with alopecia areata who developed new central nervous system demyelination after starting tofacitinib therapy; while the drug was associated with this neurological event, causality is not confirmed. The demyelination was reversible upon stopping the medication and administering corticosteroids.

This study found that serum 3α-androstanediol glucuronide levels were higher in Indian women with female pattern hair loss and correlated with the severity of the condition.

This retrospective cohort study found that lower postoperative nadir hematocrit levels were significantly associated with higher 28-day mortality and worse secondary outcomes after coronary artery bypass grafting, with an optimal survival benefit observed when nadir hematocrit ranged from 27% to 31%.

This review article connects key systemic lupus erythematosus pathobiology with current therapies, emphasizes clinical strategies for managing comorbidities, and stresses multidisciplinary care, but it reports no new clinical findings.